CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Peplin Inc (Chess) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Peplin Inc (Chess)
6475 Christie Avenue
Phone: (510) 653-9700p:510 653-9700 Emeryville, CA  94608  United States Ticker: PLI PLI
This company was Merged or Acquired on 11/12/2009.
This company ceased filing statements with the SEC on 11/17/2009.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Peplin, Inc. (Peplin) is a development-stage specialty pharmaceutical company focused on advancing and commercializing medical dermatology products. The Company is developing PEP005 (ingenol mebutate) (PEP005), which is derived from Euphorbia peplus (E. peplus), a plant referred to as petty spurge or radium weed. The Company’s lead product candidate, which is in Phase III clinical trials, is a patient-applied topical gel containing PEP005, a compound used for the treatment of actinic keratosis (AK). Peplin’s other product candidate is a physician-applied topical gel for the treatment of superficial basal cell carcinoma (superficial BCC), PEP005 Gel for BCC. The active compound in each product is a small molecule extracted and purified from the sap of E. peplus. On October 16, 2008, the Company acquired Neosil, Inc., a dermatology-focused company.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20096/30/2009YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
2833 Medicinal chemicals and botanical products

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer Thomas G.Wiggans 57 8/19/2008 10/16/2007
President, Chief Medical Officer, Director Eugene A.Bauer 67 8/19/2008 6/24/2006
Chief Financial Officer, Company Secretary David J.Smith 34 9/5/2008 7/1/2004
8 additional Officers and Directors records available in full report.

Business Names
Business Name
Neosil, Inc.
Peplin Biolipids Pty Ltd
Peplin Biotech Ltd.
8 additional Business Names available in full report.

General Information
Number of Employees: 40 (As of 6/30/2009)
Outstanding Shares: 15,371,121 (As of 6/30/2009)
Shareholders: 3,839
Stock Exchange: ASX
Fax Number: (510) 653-9704


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023